타미플루(오셀타미비르 인산염) 시장(2025-2029년)

The global tamiflu oseltamivir phosphate market is forecasted to grow by USD 204.5 mn during 2024-2029, accelerating at a CAGR of 4.6% during the forecast period. The report on the global tamiflu oseltamivir phosphate market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by seasonal influenza incidence and severity, government stockpiling and pandemic preparedness policies, widespread availability and affordability of generic formulations.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global tamiflu oseltamivir phosphate market is segmented as below:

By Type

• Branded
• Generic

By Formulation

• Capsules
• Suspension

By Indication

• Influenza A
• Influenza B
• Swine flu

Geography

• Asia
• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • The Netherlands
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the increasing adoption of novel antiviral therapies as one of the prime reasons driving the global tamiflu oseltamivir phosphate market growth during the next few years. Also, strategic diversification of manufacturing footprints and integration of digital health and advanced diagnostics in clinical pathways will lead to sizable demand in the market.

The report on the global tamiflu oseltamivir phosphate market covers the following areas:

• Global tamiflu oseltamivir phosphate market sizing
• Global tamiflu oseltamivir phosphate market forecast
• Global tamiflu oseltamivir phosphate market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global tamiflu oseltamivir phosphate market vendors that include Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Cipla Inc., Epic Pharma LLC, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Hetero Labs Ltd., Jubilant Generics Ltd., Laurus Labs Ltd., Lupin Ltd., Macleods Pharmaceuticals Ltd., MSN Laboratories, NATCO Pharma Ltd., Nivagen Pharmaceuticals Inc., Strides Pharma Ltd., Teva Pharmaceutical Ltd., Viatris Inc., Zydus Group. Also, the global tamiflu oseltamivir phosphate market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Formulation
  • Executive Summary - Chart on Market Segmentation by Indication
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029

5 Historic Market Size

• 5.1 Global Tamiflu Oseltamivir Phosphate Market 2019 - 2023
  • Historic Market Size - Data Table on Global Tamiflu Oseltamivir Phosphate Market 2019 - 2023 ($ million)
• 5.2 Type segment analysis 2019 - 2023
  • Historic Market Size - Type Segment 2019 - 2023 ($ million)
• 5.3 Formulation segment analysis 2019 - 2023
  • Historic Market Size - Formulation Segment 2019 - 2023 ($ million)
• 5.4 Indication segment analysis 2019 - 2023
  • Historic Market Size - Indication Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

• 6.1 The AI impact on global tamiflu oseltamivir phosphate market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Branded - Market size and forecast 2024-2029
• 8.4 Generic - Market size and forecast 2024-2029
• 8.5 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Formulation

• 9.1 Market segments
• 9.2 Comparison by Formulation
• 9.3 Capsules - Market size and forecast 2024-2029
• 9.4 Suspension - Market size and forecast 2024-2029
• 9.5 Market opportunity by Formulation
  • Market opportunity by Formulation ($ million)

10 Market Segmentation by Indication

• 10.1 Market segments
• 10.2 Comparison by Indication
• 10.3 Influenza A - Market size and forecast 2024-2029
• 10.4 Influenza B - Market size and forecast 2024-2029
• 10.5 Swine flu - Market size and forecast 2024-2029
• 10.6 Market opportunity by Indication
  • Market opportunity by Indication ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 Asia - Market size and forecast 2024-2029
  • 12.3.1 China - Market size and forecast 2024-2029
  • 12.3.2 Japan - Market size and forecast 2024-2029
  • 12.3.3 India - Market size and forecast 2024-2029
  • 12.3.4 South Korea - Market size and forecast 2024-2029
  • 12.3.5 Indonesia - Market size and forecast 2024-2029
  • 12.3.6 Singapore - Market size and forecast 2024-2029
  • 12.3.7 Thailand - Market size and forecast 2024-2029
• 12.4 North America - Market size and forecast 2024-2029
  • 12.4.1 US - Market size and forecast 2024-2029
  • 12.4.2 Canada - Market size and forecast 2024-2029
  • 12.4.3 Mexico - Market size and forecast 2024-2029
• 12.5 Europe - Market size and forecast 2024-2029
  • 12.5.1 Germany - Market size and forecast 2024-2029
  • 12.5.2 France - Market size and forecast 2024-2029
  • 12.5.3 UK - Market size and forecast 2024-2029
  • 12.5.4 Italy - Market size and forecast 2024-2029
  • 12.5.5 Spain - Market size and forecast 2024-2029
  • 12.5.6 Russia - Market size and forecast 2024-2029
  • 12.5.7 The Netherlands - Market size and forecast 2024-2029
• 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
  • 12.6.1 Brazil - Market size and forecast 2024-2029
  • 12.6.2 South Africa - Market size and forecast 2024-2029
  • 12.6.3 Saudi Arabia - Market size and forecast 2024-2029
  • 12.6.4 UAE - Market size and forecast 2024-2029
  • 12.6.5 Australia - Market size and forecast 2024-2029
  • 12.6.6 Turkey - Market size and forecast 2024-2029
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Seasonal influenza incidence and severity
  • Government stockpiling and pandemic preparedness policies
  • Widespread availability and affordability of generic formulations
• 13.2 Market challenges
  • Intense generic competition and severe price erosion
  • High threat from substitute products and preventative measures
  • Demand volatility and complex supply chain management
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 13.4 Market opportunities
  • Increasing adoption of novel antiviral therapies
  • Strategic diversification of manufacturing footprints
  • Integration of digital health and advanced diagnostics in clinical pathways

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Alembic Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Ltd. - Overview
  • Alembic Pharmaceuticals Ltd. - Product / Service
  • Alembic Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.5 Amneal Pharmaceuticals Inc.
  • Amneal Pharmaceuticals Inc. - Overview
  • Amneal Pharmaceuticals Inc. - Business segments
  • Amneal Pharmaceuticals Inc. - Key news
  • Amneal Pharmaceuticals Inc. - Key offerings
  • Amneal Pharmaceuticals Inc. - Segment focus
  • SWOT
• 15.6 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Product / Service
  • Aurobindo Pharma Ltd. - Key offerings
  • SWOT
• 15.7 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.8 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.9 Gilead Sciences Inc.
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Product / Service
  • Gilead Sciences Inc. - Key news
  • Gilead Sciences Inc. - Key offerings
  • SWOT
• 15.10 Laurus Labs Ltd.
  • Laurus Labs Ltd. - Overview
  • Laurus Labs Ltd. - Product / Service
  • Laurus Labs Ltd. - Key offerings
  • SWOT
• 15.11 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.12 Macleods Pharmaceuticals Ltd.
  • Macleods Pharmaceuticals Ltd. - Overview
  • Macleods Pharmaceuticals Ltd. - Product / Service
  • Macleods Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.13 MSN Laboratories
  • MSN Laboratories - Overview
  • MSN Laboratories - Product / Service
  • MSN Laboratories - Key offerings
  • SWOT
• 15.14 NATCO Pharma Ltd.
  • NATCO Pharma Ltd. - Overview
  • NATCO Pharma Ltd. - Product / Service
  • NATCO Pharma Ltd. - Key offerings
  • SWOT
• 15.15 Strides Pharma Ltd.
  • Strides Pharma Ltd. - Overview
  • Strides Pharma Ltd. - Product / Service
  • Strides Pharma Ltd. - Key offerings
  • SWOT
• 15.16 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.17 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT
• 15.18 Zydus Group
  • Zydus Group - Overview
  • Zydus Group - Product / Service
  • Zydus Group - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations